

Supplementary Figure 1. (A) Serum levels of IL-8 before TACE significantly correlate with the target lesions' longitudinal changes of size after TACE. (B and C) Serum concentrations of IL-6 and CCL22 do not significantly correlate with a change of size of the target lesion after TACE

Supplementary Figure 2. (A) Patients with high pre-interventional IL-8 serum levels (above the 50th percentile) have a significantly impaired long term survival after TACE therapy compared to patients with low IL-8 serum levels. (B and C) Serum levels of IL-6 and CCL22 above and below the 50th percentile are unable to identify patients with an unfavourable prognosis.

Supplementary Figure 3. (A-C) Serum levels of IL-8, IL-6 and CCL22 at day 1 after TACE are unaltered between patients who showed an objective response (OR) to TACE and non-responding (non-OR) patients. (D-F) Serum levels of IL-8, IL-6 and CCL22 at day 2 after TACE do not differ between OR and non-OR patients.